Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Industry: Pharma & Healthcare

Published Date: 2025-03-28

Pages: 135 Pages

Report ld: 4669875

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Varicella Vaccine Market Size(US$)

CAGR 2025-2031

7.8%

Market Size,2031

USD 8,137

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 5,185 million

Market Forecast in 2031(Value)

US$ 8,137 million

CAGR

7.8%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.

Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.

In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Varicella Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Vaccine.

The Varicella Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Varicella Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Varicella Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

By Company

Merck

GSK

Shanghai Institute

BCHT

Changsheng

Keygen

Green Cross

Biken

Segment by Type

Injection

Freeze-Dried Powder

Segment by Application

Kids Injection

Adults Injection

By Region

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Varicella Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 3: Detailed analysis of Varicella Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Varicella Vaccine sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.

Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.

Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.

Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.

Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: Research Findings and Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Varicella Vaccine Product Introduction

1.2 Market by Type

1.2.1 Global Varicella Vaccine Market Size Growth Rate by Type (2020 VS 2024 VS 2031)

1.2.2 Injection

1.2.3 Freeze-Dried Powder

1.3 Market by Application

1.3.1 Global Varicella Vaccine Market Size Growth Rate by Application (2020 VS 2024 VS 2031)

1.3.2 Kids Injection

1.3.3 Adults Injection

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Varicella Vaccine Market Size Estimates and Forecasts

2.1.1 Global Varicella Vaccine Revenue 2020-2031

2.1.2 Global Varicella Vaccine Sales 2020-2031

2.2 Varicella Vaccine Market Size by Region: 2024 Versus 2031

2.3 Varicella Vaccine Sales by Region (2020-2031)

2.3.1 Global Varicella Vaccine Sales by Region: 2020-2025

2.3.2 Global Varicella Vaccine Sales Forecast by Region (2026-2031)

2.3.3 Global Varicella Vaccine Sales Market Share by Region (2020-2031)

2.4 Varicella Vaccine Market Estimates and Projections by Region (2026-2031)

2.4.1 Global Varicella Vaccine Revenue by Region: 2020-2025

2.4.2 Global Varicella Vaccine Revenue Forecast by Region (2026-2031)

2.4.3 Global Varicella Vaccine Revenue Market Share by Region (2020-2031)

3 Market Segments

3.1 Breakdown Data by Type

3.1.1 Global Varicella Vaccine Sales by Type (2020-2031)

3.1.1.1 Global Varicella Vaccine Sales Volume by Type (2020-2031)

3.1.1.2 Global Varicella Vaccine Sales Market Share by Type (2020-2031)

3.1.2 Global Varicella Vaccine Revenue by Type (2020-2031)

3.1.2.1 Global Varicella Vaccine Revenue by Type (2020-2031)

3.1.2.2 Global Varicella Vaccine Revenue Market Share by Type (2020-2031)

3.1.3 Varicella Vaccine Average Selling Price (ASP) by Type (2020-2031)

3.2 Breakdown Data by Application

3.2.1 Global Varicella Vaccine Sales by Application (2020-2031)

3.2.1.1 Global Varicella Vaccine Sales Volume by Application (2020-2031)

3.2.1.2 Global Varicella Vaccine Sales Market Share by Application (2020-2031)

3.2.2 Global Varicella Vaccine Revenue by Application (2020-2031)

3.2.2.1 Global Varicella Vaccine Revenue by Application (2020-2031)

3.2.2.2 Global Varicella Vaccine Revenue Market Share by Application (2020-2031)

3.2.3 Varicella Vaccine Average Selling Price (ASP) by Application (2020-2031)

3.3 by Type and by Application Crossing Analysis

3.3.1 Injection of Varicella Vaccine Revenue Market Share by Application

3.3.2 Freeze-Dried Powder of Varicella Vaccine Revenue Market Share by Application

4 Global Varicella Vaccine by Manufacturers

4.1 Global Top Varicella Vaccine Manufacturers by Sales (2020-2025)

4.1.1 Global Varicella Vaccine Sales by Manufacturer (2020-2025)

4.1.2 Global Varicella Vaccine Sales Market Share by Manufacturer (2020-2025)

4.2 Global Top Varicella Vaccine Manufacturers by Revenue (2020-2025)

4.2.1 Global Varicella Vaccine Revenue by Manufacturer (2020-2025)

4.2.2 Global Varicella Vaccine Revenue Share by Manufacturer (2020-2025)

4.3 Global Varicella Vaccine Price by Manufacturer (2020-2025)

4.4 Competitive Landscape

4.4.1 Key Varicella Vaccine Manufacturers Covered: Ranking by Revenue

4.4.2 Global Varicella Vaccine Market Concentration Ratio (CR5 and HHI) & (2020-2025)

4.4.3 Global Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.5 Global Varicella Vaccine Manufacturing Base Distribution, Product Type

4.5.1 Varicella Vaccine Manufacturers Manufacturing Base Distribution, Headquarters

4.5.2 Date of International Manufacturers Enter into Varicella Vaccine Market

4.5.3 Manufacturers Varicella Vaccine Product Type and Application

4.5.4 Injection Market Sales of Varicella Vaccine by Manufacturer

4.5.5 Freeze-Dried Powder Market Sales of Varicella Vaccine by Manufacturer

4.6 Manufacturers Mergers & Acquisitions, Expansion Plans

5 Company Profiles

5.1 Merck

5.1.1 Merck Company Information

5.1.2 Merck Description, Business Overview

5.1.3 Merck Varicella Vaccine Products Offered

5.1.4 Merck Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.1.5 Merck Varicella Vaccine Sales by Product in 2024

5.1.6 Merck Varicella Vaccine Sales by Application in 2024

5.1.7 Merck Varicella Vaccine Sales by Geographic Area in 2024

5.1.8 Merck Recent Developments

5.2 GSK

5.2.1 GSK Company Information

5.2.2 GSK Description, Business Overview

5.2.3 GSK Varicella Vaccine Products Offered

5.2.4 GSK Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.2.5 GSK Varicella Vaccine Sales by Product in 2024

5.2.6 GSK Varicella Vaccine Sales by Application in 2024

5.2.7 GSK Varicella Vaccine Sales by Geographic Area in 2024

5.2.8 GSK Recent Developments

5.3 Shanghai Institute

5.3.1 Shanghai Institute Company Information

5.3.2 Shanghai Institute Description, Business Overview

5.3.3 Shanghai Institute Varicella Vaccine Products Offered

5.3.4 Shanghai Institute Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.3.5 Shanghai Institute Varicella Vaccine Sales by Product in 2024

5.3.6 Shanghai Institute Varicella Vaccine Sales by Application in 2024

5.3.7 Shanghai Institute Varicella Vaccine Sales by Geographic Area in 2024

5.3.8 Shanghai Institute Recent Developments

5.4 BCHT

5.4.1 BCHT Company Information

5.4.2 BCHT Description, Business Overview

5.4.3 BCHT Varicella Vaccine Products Offered

5.4.4 BCHT Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.4.5 BCHT Varicella Vaccine Sales by Product in 2024

5.4.6 BCHT Varicella Vaccine Sales by Application in 2024

5.4.7 BCHT Varicella Vaccine Sales by Geographic Area in 2024

5.4.8 BCHT Recent Developments

5.5 Changsheng

5.5.1 Changsheng Company Information

5.5.2 Changsheng Description, Business Overview

5.5.3 Changsheng Varicella Vaccine Products Offered

5.5.4 Changsheng Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.5.5 Changsheng Varicella Vaccine Sales by Product in 2024

5.5.6 Changsheng Varicella Vaccine Sales by Application in 2024

5.5.7 Changsheng Varicella Vaccine Sales by Geographic Area in 2024

5.5.8 Changsheng Recent Developments

5.6 Keygen

5.6.1 Keygen Company Information

5.6.2 Keygen Description, Business Overview

5.6.3 Keygen Varicella Vaccine Products Offered

5.6.4 Keygen Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.6.5 Keygen Varicella Vaccine Sales by Product in 2024

5.6.6 Keygen Varicella Vaccine Sales by Application in 2024

5.6.7 Keygen Varicella Vaccine Sales by Geographic Area in 2024

5.6.8 Keygen Recent Developments

5.7 Green Cross

5.7.1 Green Cross Company Information

5.7.2 Green Cross Description, Business Overview

5.7.3 Green Cross Varicella Vaccine Products Offered

5.7.4 Green Cross Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.7.5 Green Cross Varicella Vaccine Sales by Product in 2024

5.7.6 Green Cross Varicella Vaccine Sales by Application in 2024

5.7.7 Green Cross Varicella Vaccine Sales by Geographic Area in 2024

5.7.8 Green Cross Recent Developments

5.8 Biken

5.8.1 Biken Company Information

5.8.2 Biken Description, Business Overview

5.8.3 Biken Varicella Vaccine Products Offered

5.8.4 Biken Varicella Vaccine Sales, Revenue and Gross Margin (2020-2025)

5.8.5 Biken Varicella Vaccine Sales by Product in 2024

5.8.6 Biken Varicella Vaccine Sales by Application in 2024

5.8.7 Biken Varicella Vaccine Sales by Geographic Area in 2024

5.8.8 Biken Recent Developments

6 North America

6.1 North America Varicella Vaccine Market Size YoY Growth 2020-2031

6.2 North America Varicella Vaccine Market Facts & Figures by Country

6.2.1 North America Varicella Vaccine Sales by Country (2020-2031)

6.2.2 North America Varicella Vaccine Revenue by Country (2020-2031)

6.3 North America Varicella Vaccine Sales by Type (2020-2025)

6.4 North America Varicella Vaccine Sales by Application (2020-2025)

7 Asia-Pacific

7.1 Asia-Pacific Varicella Vaccine Market Size YoY Growth 2020-2031

7.2 Asia-Pacific Varicella Vaccine Market Facts & Figures by Region

7.2.1 Asia-Pacific Varicella Vaccine Sales by Region (2020-2031)

7.2.2 Asia-Pacific Varicella Vaccine Revenue by Region (2020-2031)

7.3 Asia-Pacific Varicella Vaccine Sales by Type (2020-2025)

7.4 Asia-Pacific Varicella Vaccine Sales by Application (2020-2025)

8 Europe

8.1 Europe Varicella Vaccine Market Size YoY Growth 2020-2031

8.2 Europe Varicella Vaccine Market Facts & Figures by Country

8.2.1 Europe Varicella Vaccine Sales by Country (2020-2031)

8.2.2 Europe Varicella Vaccine Revenue by Country (2020-2031)

8.3 Europe Varicella Vaccine Sales by Type (2020-2025)

8.4 Europe Varicella Vaccine Sales by Application (2020-2025)

9 Latin America

9.1 Latin America Varicella Vaccine Market Size YoY Growth 2020-2031

9.2 Latin America Varicella Vaccine Market Facts & Figures by Country

9.2.1 Latin America Varicella Vaccine Sales by Country (2020-2031)

9.2.2 Latin America Varicella Vaccine Revenue by Country (2020-2031)

9.3 Latin America Varicella Vaccine Sales by Type (2020-2025)

9.4 Latin America Varicella Vaccine Sales by Application (2020-2025)

10 Middle East and Africa

10.1 Latin America Varicella Vaccine Market Size YoY Growth 2020-2031

10.2 Middle East and Africa Varicella Vaccine Market Facts & Figures by Country

10.2.1 Middle East and Africa Varicella Vaccine Sales by Country (2020-2031)

10.2.2 Middle East and Africa Varicella Vaccine Revenue by Country (2020-2031)

10.3 Middle East and Africa Varicella Vaccine Sales by Type (2020-2025)

10.4 Middle East and Africa Varicella Vaccine Sales by Application (2020-2025)

11 Supply Chain and Sales Channel analysis

11.1 Varicella Vaccine Supply Chain Analysis

11.2 Varicella Vaccine Key Raw Materials and Upstream Suppliers

11.3 Varicella Vaccine Clients Analysis

11.4 Varicella Vaccine Sales Channel and Sales Model Analysis

11.4.1 Varicella Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales

11.4.2 Varicella Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales

11.4.3 Varicella Vaccine Distributors

12 Varicella Vaccine Market Dynamics

12.1 Varicella Vaccine Industry Trends

12.2 Varicella Vaccine Market Drivers

12.3 Varicella Vaccine Market Challenges

12.4 Varicella Vaccine Market Restraints

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.1.1 Research Programs/Design

14.1.1.2 Market Size Estimation

14.1.1.3 Market Breakdown and Data Triangulation

14.1.2 Data Source

14.1.2.1 Secondary Sources

14.1.2.2 Primary Sources

14.2 Author Details

14.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Varicella Vaccine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Varicella Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Varicella Vaccine Market Size by Region (US$ Million): 2024 VS 2031

Table 4. Global Varicella Vaccine Sales by Region (2020-2025) & (M Doses)

Table 5. Global Varicella Vaccine Sales Forecast by Region (2026-2031) & (M Doses)

Table 6. Global Varicella Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 7. Global Varicella Vaccine Revenue Forecast by Region (2026-2031) & (US$ Million)

Table 8. Global Varicella Vaccine Sales Volume by Type (2020-2025) & (M Doses)

Table 9. Global Varicella Vaccine Sales Volume by Type (2026-2031) & (M Doses)

Table 10. Global Varicella Vaccine Revenue by Type (2020-2025) & (US$ Million)

Table 11. Global Varicella Vaccine Revenue Forecast by Type (2026-2031) & (US$ Million)

Table 12. Global Varicella Vaccine Sales Volume by Application (2020-2025) & (M Doses)

Table 13. Global Varicella Vaccine Sales Volume by Application (2026-2031) & (M Doses)

Table 14. Global Varicella Vaccine Revenue by Application (2020-2025) & (US$ Million)

Table 15. Global Varicella Vaccine Revenue by Application (2026-2031) & (US$ Million)

Table 16. Global Varicella Vaccine Sales by Manufacturer (2020-2025) & (M Doses)

Table 17. Global Varicella Vaccine Sales Share by Manufacturer (2020-2025)

Table 18. Varicella Vaccine Revenue by Manufacturer (2020-2025) & (US$ Million)

Table 19. Varicella Vaccine Revenue Share by Manufacturer (2020-2025)

Table 20. Key Manufacturers Varicella Vaccine Price (2020-2025) & (USD/Dose)

Table 21. Ranking of Global Top Varicella Vaccine Manufacturers by Revenue (US$ Million) in 2024

Table 22. Global Varicella Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)

Table 23. Global Varicella Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Vaccine as of 2024)

Table 24. Varicella Vaccine Manufacturers Manufacturing Base Distribution and Headquarters

Table 25. Date of International Manufacturers Enter into Varicella Vaccine Market

Table 26. Manufacturers Varicella Vaccine Product Type and Application

Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 28. Merck Company Information

Table 29. Merck Description and Business Overview

Table 30. Merck Varicella Vaccine Product

Table 31. Merck Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 32. Merck Sales Proportion of Varicella Vaccine by Product in 2024

Table 33. Merck Sales Proportion of Varicella Vaccine by Application in 2024

Table 34. Merck Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 35. Merck Recent Developments

Table 36. GSK Company Information

Table 37. GSK Description and Business Overview

Table 38. GSK Varicella Vaccine Product

Table 39. GSK Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 40. GSK Sales Proportion of Varicella Vaccine by Product in 2024

Table 41. GSK Sales Proportion of Varicella Vaccine by Application in 2024

Table 42. GSK Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 43. GSK Recent Developments

Table 44. Shanghai Institute Company Information

Table 45. Shanghai Institute Description and Business Overview

Table 46. Shanghai Institute Varicella Vaccine Product

Table 47. Shanghai Institute Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 48. Shanghai Institute Sales Proportion of Varicella Vaccine by Product in 2024

Table 49. Shanghai Institute Sales Proportion of Varicella Vaccine by Application in 2024

Table 50. Shanghai Institute Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 51. Shanghai Institute Recent Developments

Table 52. BCHT Company Information

Table 53. BCHT Description and Business Overview

Table 54. BCHT Varicella Vaccine Product

Table 55. BCHT Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 56. BCHT Sales Proportion of Varicella Vaccine by Product in 2024

Table 57. BCHT Sales Proportion of Varicella Vaccine by Application in 2024

Table 58. BCHT Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 59. BCHT Recent Developments

Table 60. Changsheng Company Information

Table 61. Changsheng Description and Business Overview

Table 62. Changsheng Varicella Vaccine Product

Table 63. Changsheng Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 64. Changsheng Sales Proportion of Varicella Vaccine by Product in 2024

Table 65. Changsheng Sales Proportion of Varicella Vaccine by Application in 2024

Table 66. Changsheng Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 67. Changsheng Recent Developments

Table 68. Keygen Company Information

Table 69. Keygen Description and Business Overview

Table 70. Keygen Varicella Vaccine Product

Table 71. Keygen Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 72. Keygen Sales Proportion of Varicella Vaccine by Product in 2024

Table 73. Keygen Sales Proportion of Varicella Vaccine by Application in 2024

Table 74. Keygen Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 75. Keygen Recent Developments

Table 76. Green Cross Company Information

Table 77. Green Cross Description and Business Overview

Table 78. Green Cross Varicella Vaccine Product

Table 79. Green Cross Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 80. Green Cross Sales Proportion of Varicella Vaccine by Product in 2024

Table 81. Green Cross Sales Proportion of Varicella Vaccine by Application in 2024

Table 82. Green Cross Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 83. Green Cross Recent Developments

Table 84. Biken Company Information

Table 85. Biken Description and Business Overview

Table 86. Biken Varicella Vaccine Product

Table 87. Biken Varicella Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 88. Biken Sales Proportion of Varicella Vaccine by Product in 2024

Table 89. Biken Sales Proportion of Varicella Vaccine by Application in 2024

Table 90. Biken Sales Proportion of Varicella Vaccine by Geographic Area in 2024

Table 91. Biken Recent Developments

Table 92. North America Varicella Vaccine Sales by Country (2020-2025) & (M Doses)

Table 93. North America Varicella Vaccine Sales by Country (2026-2031) & (M Doses)

Table 94. North America Varicella Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 95. North America Varicella Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 96. North America Varicella Vaccine Sales by Type (2020-2025) & (M Doses)

Table 97. North America Varicella Vaccine Sales by Application (2020-2025) & (M Doses)

Table 98. Asia-Pacific Varicella Vaccine Sales by Region (2020-2025) & (M Doses)

Table 99. Asia-Pacific Varicella Vaccine Sales by Region (2026-2031) & (M Doses)

Table 100. Asia-Pacific Varicella Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 101. Asia-Pacific Varicella Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 102. Asia-Pacific Varicella Vaccine Sales by Type (2020-2025) & (M Doses)

Table 103. Asia-Pacific Varicella Vaccine Sales by Application (2020-2025) & (M Doses)

Table 104. Europe Varicella Vaccine Sales by Country (2020-2025) & (M Doses)

Table 105. Europe Varicella Vaccine Sales by Country (2026-2031) & (M Doses)

Table 106. Europe Varicella Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 107. Europe Varicella Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 108. Europe Varicella Vaccine Sales by Type (2020-2025) & (M Doses)

Table 109. Europe Varicella Vaccine Sales by Application (2020-2025) & (M Doses)

Table 110. Latin America Varicella Vaccine Sales by Country (2020-2025) & (M Doses)

Table 111. Latin America Varicella Vaccine Sales by Country (2026-2031) & (M Doses)

Table 112. Latin America Varicella Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 113. Latin America Varicella Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 114. Latin America Varicella Vaccine Sales by Type (2020-2025) & (M Doses)

Table 115. Latin America Varicella Vaccine Sales by Application (2020-2025) & (M Doses)

Table 116. Middle East and Africa Varicella Vaccine Sales by Country (2020-2025) & (M Doses)

Table 117. Middle East and Africa Varicella Vaccine Sales by Country (2026-2031) & (M Doses)

Table 118. Middle East and Africa Varicella Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 119. Middle East and Africa Varicella Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 120. Middle East and Africa Varicella Vaccine Sales by Type (2020-2025) & (M Doses)

Table 121. Middle East and Africa Varicella Vaccine Sales by Application (2020-2025) & (M Doses)

Table 122. Varicella Vaccine Key Raw Materials, Industry Status and Trend

Table 123. Varicella Vaccine Key Raw Materials and Upstream Suppliers

Table 124. Varicella Vaccine Clients Status and Trend

Table 125. Varicella Vaccine Typical Clients

Table 126. Varicella Vaccine Distributors

Table 127. Varicella Vaccine Market Trends

Table 128. Varicella Vaccine Market Drivers

Table 129. Varicella Vaccine Market Challenges

Table 130. Varicella Vaccine Market Restraints

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

Table 134. QYR Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Varicella Vaccine Product Picture

Figure 2. Global Varicella Vaccine Market Size by Type (US$ Million): 2020 VS 2024 VS 2031

Figure 3. Global Varicella Vaccine Sales Market Share by Type in 2024 & 2031

Figure 4. Injection Product Picture

Figure 5. Freeze-Dried Powder Product Picture

Figure 6. Global Varicella Vaccine Market Size by Application (US$ Million): 2020 VS 2024 VS 2031

Figure 7. Global Varicella Vaccine Sales Market Share by Application in 2024 & 2031

Figure 8. Kids Injection

Figure 9. Adults Injection

Figure 10. Varicella Vaccine Report Years Considered

Figure 11. Global Varicella Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Varicella Vaccine Market Size 2020-2031 (US$ Million)

Figure 13. Global Varicella Vaccine Sales 2020-2031 (M Doses)

Figure 14. Global Varicella Vaccine Sales Market Share Forecast by Region (2020-2031)

Figure 15. Global Varicella Vaccine Revenue Market Share by Region (2020-2031)

Figure 16. Global Varicella Vaccine Sales Market Share Forecast by Type (2020-2031)

Figure 17. Global Varicella Vaccine Revenue Market Share Forecast by Type (2020-2031)

Figure 18. Varicella Vaccine Average Selling Price (ASP) by Type (2020-2025) & (USD/Dose)

Figure 19. Global Varicella Vaccine Sales Market Share Forecast by Application (2020-2031)

Figure 20. Global Varicella Vaccine Revenue Market Share Forecast by Application (2020-2031)

Figure 21. Varicella Vaccine Average Selling Price (ASP) by Application (2020-2025) & (USD/Dose)

Figure 22. Injection of Varicella Vaccine Revenue Market Share by Application, 2024 VS 2031

Figure 23. Freeze-Dried Powder of Varicella Vaccine Revenue Market Share by Application, 2024 VS 2031

Figure 24. Global Varicella Vaccine Sales Share by Manufacturer in 2024

Figure 25. Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 26. Injection Market Sales Proportion by Manufacturer in 2024

Figure 27. Freeze-Dried Powder Market Sales Proportion by Manufacturer in 2024

Figure 28. North America Varicella Vaccine Revenue 2020-2031 (US$ Million)

Figure 29. North America Varicella Vaccine Sales Market Share by Type (2020-2025)

Figure 30. North America Varicella Vaccine Sales Market Share by Application (2020-2025)

Figure 31. Asia-Pacific Varicella Vaccine Revenue 2020-2031 (US$ Million)

Figure 32. Asia-Pacific Varicella Vaccine Sales Market Share by Region (2020-2031)

Figure 33. Asia-Pacific Varicella Vaccine Revenue Market Share by Region (2020-2031)

Figure 34. Asia-Pacific Varicella Vaccine Sales Market Share by Type (2020-2025)

Figure 35. Asia-Pacific Varicella Vaccine Sales Market Share by Application (2020-2025)

Figure 36. Europe Varicella Vaccine Revenue Growth Rate 2020-2031 (US$ Million)

Figure 37. Europe Varicella Vaccine Sales Market Share by Country (2020-2031)

Figure 38. Europe Varicella Vaccine Revenue Market Share by Country (2020-2031)

Figure 39. Europe Varicella Vaccine Sales Market Share by Type (2020-2025)

Figure 40. Europe Varicella Vaccine Sales Market Share by Application (2020-2025)

Figure 41. Latin America Varicella Vaccine Revenue Growth Rate 2020-2031 (US$ Million)

Figure 42. Latin America Varicella Vaccine Sales Market Share by Country (2020-2031)

Figure 43. Latin America Varicella Vaccine Revenue Market Share by Country (2020-2025)

Figure 44. Latin America Varicella Vaccine Sales Market Share by Type (2020-2025)

Figure 45. Latin America Varicella Vaccine Sales Market Share by Application (2020-2025)

Figure 46. Middle East and Africa Varicella Vaccine Revenue Growth Rate 2020-2031 (US$ Million)

Figure 47. Middle East and Africa Varicella Vaccine Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa Varicella Vaccine Revenue Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Varicella Vaccine Sales Market Share by Type (2020-2025)

Figure 50. Middle East and Africa Varicella Vaccine Sales Market Share by Application (2020-2025)

Figure 51. Varicella Vaccine Supply Chain (Upstream and Downstream Market)

Figure 52. Global Production Market Share of Varicella Vaccine Raw Materials by Region in 2024

Figure 53. Varicella Vaccine Distribution Channels

Figure 54. Global Varicella Vaccine Percentage 2020-2031: Indirect Sales VS Direct Sales

Figure 55. Global Varicella Vaccine Percentage 2020-2031: Online Sales VS Offline Sales

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

Figure 58. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What was the global market size of Varicella Vaccine in 2025? shouQi

What was the global market size of Varicella Vaccine in 2031? shouQi

What is the annual compound growth rate of the global Varicella Vaccine market size from 2025 to 2031? shouQi

Which companies rank high in the global Varicella Vaccine market? shouQi

Related Reports

Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 114
USD 2900.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 149
USD 4900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 77
USD 4250.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)

Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)
Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 114
USD 2900.00 (Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
USD 3950.00 (Single User License)
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 149
USD 4900.00 (Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 77
USD 4250.00 (Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
USD 2900.00 (Single User License)
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-17
Pages: 140
USD 5600.00 (Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
USD 5900.00 (Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
USD 4900.00 (Single User License)